Patna,(BiharTimes): Noted physician and diabetes specialist of Patna, Dr
Ajay Kumar, has contributed as one of the Principal Investigators in
the clinical research and development of new insulin called, Insulin
Degludec. This molecule has been developed by Danish pharmaceutical
company Novo Nordisk.
Dr Ajay Kumar returned from London on Sunday after
presenting his analysis of the research data at the Insulin Degludec
result meeting held there on November 16.
It is an ultra long
acting drug with a half life of 25 hours. This makes it eminently
suitable for once daily administration to keep the blood sugar control
for 24 hours a day.
Another advantage is significant reduction in the incidence of
hypoglycemia (low blood sugar), which is a big problem with existing
insulins. Insulin Degludec reduces both total and nocturnal
hypoglycemia. Nocturnal hypoglycemia can be particularly dangerous as
the subject might not be aware of its occurrence and may not take
corrective steps to treat.
Unlike currently available insulins, Degludec does not cause
significant weight gain. This is considered a big advantage as any
weight gain in a diabetic subject might increase the risk of heart
disease.
Degludec can be injected at any time of the day depending upon what
might be the largest meal for that particular individual. This
flexibility is going to make it very user friendly and yet achieve the
best possible blood sugar control.
Dr Ajay Kumar presented the analysis regarding one of the most
wonderful properties of Insulin Degludec called reduced glucose
variability. Peaks and nadirs of blood sugar fluctuations are
extremely dangerous with respect to development of heart disease and
other complications of diabetes affecting kidneys, eyes, nerves and
other organs of human body. Insulin Degludec has shown to reduce the
glucose
variability in comparison to the existing insulins. This could be
helpful in reducing the diabetic complications, incidence of
hypoglycemia and overall mortality from diabetes
No comments:
Post a Comment